文献速递肝病消化道肿瘤与早癌

规避肿瘤内异质性以识别肝细胞癌潜在治疗靶点

Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2017-03-18

研究对5例患者32份多区域肿瘤样本行全外显子组测序和靶向深度测序,并测序匹配的术前循环游离DNA,比较单份肿瘤标本与cfDNA的突变谱分析效率,发现单份肿瘤标本靶向深度测序可识别约70%的总突变,优于cfDNA的47.2%,可用于筛选可操作突变。

要点

  • 靶向深度测序测得异质性28.1%,低于全外显子组测序的34.9%(p<0.01)。
  • 单份肿瘤标本靶向深度测序平均识别多区域组织总突变的70%。
  • 66例患者单份肿瘤标本及4例不可切除肝细胞癌cfDNA中,38.6%(26/66和1/4)携带潜在治疗靶点突变。

核心结论

  • 单份肿瘤标本的靶向深度测序可识别肝细胞癌中可用于治疗的可操作突变靶点。
  • cfDNA可作为分析肝细胞癌基因组的次要替代选择。

研究设计与样本

  • 对5例患者的32份多区域肿瘤样本行全外显子组测序和靶向深度测序,并测序匹配的术前循环游离DNA。
  • 以非普遍突变(存在于部分肿瘤区域)的平均百分比衡量肿瘤内异质性。
  • 比较单份肿瘤标本与cfDNA的突变谱分析效率,并用表现最高的策略筛选可操作突变。
  • 另在66例患者的单份肿瘤标本和4例不可切除肝细胞癌的cfDNA中行靶向深度测序。

主要发现

  • 观察到不同水平的异质性,呈分支和平行演化模式。
  • 靶向深度测序测得的异质性为28.1%,低于全外显子组测序的34.9%(p<0.01),增加样本分析后异质性不变。
  • 单份肿瘤标本靶向深度测序平均识别多区域组织总突变的70%。
  • cfDNA的基因组分析效率随测序深度增加而提高,但靶向深度测序平均仅识别47.2%的总突变,提示组织样本优于cfDNA。
  • 66例患者单份肿瘤标本及4例不可切除肝细胞癌cfDNA中,38.6%(26/66和1/4)携带潜在治疗靶点突变。

临床怎么用

  • 作者认为,单份肿瘤标本靶向深度测序可识别肝细胞癌中可用于治疗的可操作突变靶点。
  • 作者认为,cfDNA可作为分析肝细胞癌基因组的次要替代选择。
  • 作者指出,识别突变可能帮助临床医生选择靶向治疗以改善个体化治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Identifying target genetic mutations in hepatocellular carcinoma (HCC) for therapy is made challenging by intratumoral heterogeneity. Circulating cell-free DNAs (cfDNA) may contain a more complete mutational spectrum compared to a single tumor sample. This study aimed to identify the most efficient strategy to identify all the mutations within heterogeneous HCCs. METHODS: Whole exome sequencing (WES) and targeted deep sequencing (TDS) were carried out in 32 multi-regional tumor samples from five patients. Matched preoperative cfDNAs were sequenced accordingly. Intratumoral heterogeneity was measured using the average percentage of non-ubiquitous mutations (present in parts of tumor regions). Profiling efficiencies of single tumor specimen and cfDNA were compared. The strategy with the highest performance was used to screen for actionable mutations. RESULTS: Variable levels of heterogeneity with branched and parallel evolution patterns were observed. The heterogeneity decreased at higher sequencing depth of TDS compared to measurements by WES (28.1% vs. 34.9%, p<0.01) but remained unchanged when additional samples were analyzed. TDS of single tumor specimen identified an average of 70% of the total mutations from multi-regional tissues. Although genome profiling efficiency of cfDNA increased with sequencing depth, an average of 47.2% total mutations were identified using TDS, suggesting that tissue samples outperformed it. TDS of single tumor specimen in 66 patients and cfDNAs in four unresectable HCCs showed that 38.6% (26/66 and 1/4) of patients carried mutations that were potential therapeutic targets. CONCLUSIONS: TDS of single tumor specimen could identify actionable mutations targets for therapy in HCC. cfDNA may serve as secondary alternative in profiling HCC genome. LAY SUMMARY: Targeted deep sequencing of single tumor specimen is a more efficient method to identify mutations in hepatocellular carcinoma made from mixed subtypes compared to circulating cell-free DNA in blood. cfDNA may serve as secondary alternative in profiling HCC genome. Identifying mutations may help clinicians choose targeted therapy for better individual treatments.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Huang A, Zhao X, Yang XR, et al. Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma. J Hepatol. 2017. PMID: 28323123. doi:10.1016/j.jhep.2017.03.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。